Clinical trial

A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

NCT03355872

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-02-01

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2016-02-01Date precision: month

Registry last updated2022-05-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rheumatoid Arthritisunresolved

Interventions

HLX01DRUG

Sponsors & collaborators

Shanghai Henlius Biotechlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03355872 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.